Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
grade A 44.25 -2.49% -1.13
BHVN closed down 2.49 percent on Tuesday, February 19, 2019, on 77 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Mar 5

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BHVN trend table...

Date Alert Name Type % Chg
Feb 19 New 52 Week High Strength 0.00%
Feb 19 Wide Bands Range Expansion 0.00%
Feb 19 Overbought Stochastic Strength 0.00%
Feb 15 New 52 Week Closing High Bullish -2.49%
Feb 15 New 52 Week High Strength -2.49%
Feb 15 Wide Bands Range Expansion -2.49%
Feb 15 Overbought Stochastic Strength -2.49%
Feb 14 Bearish Engulfing Bearish 0.80%
Feb 14 New 52 Week High Strength 0.80%
Feb 14 Outside Day Range Expansion 0.80%

Older signals for BHVN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Neurodegenerative Diseases Riluzole
Is BHVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 45.68
52 Week Low 16.5
Average Volume 490,821
200-Day Moving Average 36.4488
50-Day Moving Average 37.9102
20-Day Moving Average 40.292
10-Day Moving Average 43.415
Average True Range 2.0785
ADX 31.13
+DI 25.4403
-DI 9.4848
Chandelier Exit (Long, 3 ATRs ) 39.4445
Chandelier Exit (Short, 3 ATRs ) 40.3005
Upper Bollinger Band 47.8052
Lower Bollinger Band 32.7788
Percent B (%b) 0.76
BandWidth 37.293756
MACD Line 2.1867
MACD Signal Line 1.8169
MACD Histogram 0.3699
Fundamentals Value
Market Cap 1.59 Billion
Num Shares 35.8 Million
EPS -7.54
Price-to-Earnings (P/E) Ratio -5.87
Price-to-Sales 0.00
Price-to-Book 5.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 46.94
Resistance 3 (R3) 47.11 46.40 46.49
Resistance 2 (R2) 46.40 45.71 46.31 46.34
Resistance 1 (R1) 45.32 45.29 44.97 45.15 46.19
Pivot Point 44.61 44.61 44.43 44.52 44.61
Support 1 (S1) 43.53 43.92 43.18 43.36 42.31
Support 2 (S2) 42.82 43.50 42.73 42.16
Support 3 (S3) 41.74 42.82 42.01
Support 4 (S4) 41.57